| NR2F2, also known as COUP‑TFII, is an orphan nuclear receptor of the NR2F family that binds DNA response elements as a transcription factor and controls gene programs involved in organogenesis, angiogenesis, metabolic regulation and tumor progression. The protein carries a conserved DNA‑binding domain with two zinc fingers and a ligand‑binding domain typical of nuclear receptors, and it localizes to chromatin where it recognizes direct repeat and inverted repeat nuclear receptor motifs in enhancers and promoters to modulate de novo transcription. In developmental and physiological contexts, NR2F2 integrates with pathways controlling cardiovascular and vascular development and with networks that balance proliferation and terminal differentiation, acting as a gatekeeper that adjusts cell type–specific transcriptional outputs to support proper tissue formation and energy homeostasis. In luminal A breast cancer, NR2F2 operates as a cofactor in estrogen receptor α (ERα)–mediated transcription; genome‑wide binding analyses show that NR2F2 occupies most ERα sites independently of estrogen, frequently co‑binding with pioneer factors FOXA1 and GATA3, and regions bound by all three transcription factors display the strongest ERα binding, highest activity and enrichment for super‑enhancers. Perturbation of NR2F2 expression reduces ERα DNA binding, decreases chromatin opening at ERα target loci and diminishes estrogen‑dependent cell growth, indicating that NR2F2 contributes to establishing and maintaining an accessible ERα cistrome and cooperates with FOXA1 and GATA3 to support hormone‑driven tumor growth. Across cancers, NR2F2 expression is frequently altered and the receptor has been linked to regulation of stemness, invasion, epithelial–mesenchymal transition and angiogenesis; review of multiple tumor types identifies NR2F2 as a transcriptional regulator whose upregulation or isoform switching can promote tumor renewal, metastatic spread and resistance to therapy, while in some contexts its downregulation associates with reduced malignant behavior. Mechanistically, NR2F2 can interact with TGF‑β/SMAD signaling, Wnt/β‑catenin components and PI3K/AKT‑linked networks via transcriptional control of target genes and via cooperation with other transcription factors at shared regulatory elements, positioning NR2F2 as a nodal factor in transcriptional circuitry that couples developmental pathways to oncogenic programs. Dysregulated NR2F2 has been implicated in congenital heart and vascular defects and in endocrine and solid malignancies including breast cancer and melanoma, where variant expression or alternative isoforms unleash metastatic programs or contribute to endocrine resistance. |
